Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew C Chan

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Science Translational Medicine|June 3, 2011
Rituximab's new therapeutic target: the podocyte actin cytoskeletonAndrew C Chan
Journal of Pediatric Gastroenterology and Nutrition|April 5, 2005
Defining molecular targets for drug design: synergism between academia and industryAndrew C Chan
Immunological Reviews|July 11, 2008
A golden era of opportunity in immunotherapy discovery and developmentAndrew C Chan
Molecular Immunology|January 4, 2011
B cell immunotherapy in autoimmunity--2010 updateAndrew C Chan
Immunity|May 15, 2004
Pathogenic roles of B cells in human autoimmunity; insights from the clinicFlavius Martin, Andrew C Chan
Biochemistry|November 28, 2017
Ocrelizumab: A New Therapeutic Paradigm for Multiple Sclerosis<sub>Published as part of the Biochemistry series "Biochemistry to Bedside"</sub>Peter Chin, Andrew C Chan
Annual Review of Immunology|March 23, 2006
B cell immunobiology in disease: evolving concepts from the clinicFlavius Martin, Andrew C Chan
Current Opinion in Immunology|March 14, 2003
Regulation of thymocyte development: only the meek survivePaul E Love, Andrew C Chan
Nature Reviews. Immunology|April 24, 2010
Therapeutic antibodies for autoimmunity and inflammationAndrew C Chan, Paul J Carter
Nature Immunology|January 22, 2013
Personalizing medicine for autoimmune and inflammatory diseasesAndrew C Chan, Timothy W Behrens
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Science Translational Medicine|June 3, 2011
Rituximab's new therapeutic target: the podocyte actin cytoskeletonAndrew C Chan
Journal of Pediatric Gastroenterology and Nutrition|April 5, 2005
Defining molecular targets for drug design: synergism between academia and industryAndrew C Chan
Immunological Reviews|July 11, 2008
A golden era of opportunity in immunotherapy discovery and developmentAndrew C Chan
Molecular Immunology|January 4, 2011
B cell immunotherapy in autoimmunity--2010 updateAndrew C Chan
Immunity|May 15, 2004
Pathogenic roles of B cells in human autoimmunity; insights from the clinicFlavius Martin, Andrew C Chan
Biochemistry|November 28, 2017
Ocrelizumab: A New Therapeutic Paradigm for Multiple Sclerosis<sub>Published as part of the Biochemistry series "Biochemistry to Bedside"</sub>Peter Chin, Andrew C Chan
Annual Review of Immunology|March 23, 2006
B cell immunobiology in disease: evolving concepts from the clinicFlavius Martin, Andrew C Chan
Current Opinion in Immunology|March 14, 2003
Regulation of thymocyte development: only the meek survivePaul E Love, Andrew C Chan
Nature Reviews. Immunology|April 24, 2010
Therapeutic antibodies for autoimmunity and inflammationAndrew C Chan, Paul J Carter
Nature Immunology|January 22, 2013
Personalizing medicine for autoimmune and inflammatory diseasesAndrew C Chan, Timothy W Behrens
Pageof 6